Clinical Trials Directory

Trials / Unknown

UnknownNCT00262093

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

Status
Unknown
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Hadassah Medical Organization · Academic / Other
Sex
Female
Age
Healthy volunteers
Accepted

Summary

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Detailed description

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients. We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Conditions

Timeline

Start date
2005-11-01
First posted
2005-12-06
Last updated
2007-03-20

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT00262093. Inclusion in this directory is not an endorsement.

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence (NCT00262093) · Clinical Trials Directory